Tags

Type your tag names separated by a space and hit enter

Antiviral therapy for coronavirus disease 2019.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28; 45(5):598-602.ZN

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the outbreak of coronavirus disease 2019 in Wuhan City, China. The SARS-CoV-2 is genetically similar to the coronavirus derived from bat. The SARS-CoV-2, the SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV) all belong to beta coronavirus. Since the outbreak of the coronavirus disease 2019, effective antiviral drugs have become a hot issue in the world. Very little about SARS-CoV-2 is known and there is no precedent for treatment. The National Health Commission has repeatedly revised the diagnosis and treatment guide for the coronavirus disease 2019. The latest guide is "New Coronary Virus-Infected Pneumonia Diagnosis and Treatment Plan (Seventh Trial Version)"(short for Seventh Version of Diagnosis and Treatment Plan). But the use of antiviral drugs is still on trial and no rigorous clinical trials data is available. Hot anti-SARS-CoV-2 drugs include interferon α, ribavirin, lopinavir/ritonavir, chloroquine phosphate, abidol, as well as hydroxychloroquine sulfate and remdesivir. But the later 2 drugs aren't mentioned in the Seventh Version of Diagnosis and Treatment Plan.

Authors+Show Affiliations

Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha 410011. gsb510@csu.edu.cn.Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha 410011.Department of Laboratory Medicine, Changsha Central Hospital, Nanhua University, Changsha 410004.Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha 410011.Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha 410011.Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China. shaokunliu228@csu.edu.cn.

Pub Type(s)

Journal Article

Language

eng chi

PubMed ID

32879113

Citation

Gong, Subo, et al. "Antiviral Therapy for Coronavirus Disease 2019." Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences, vol. 45, no. 5, 2020, pp. 598-602.
Gong S, Su J, Yan X, et al. Antiviral therapy for coronavirus disease 2019. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020;45(5):598-602.
Gong, S., Su, J., Yan, X., Li, F., Hu, L., & Liu, S. (2020). Antiviral therapy for coronavirus disease 2019. Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences, 45(5), 598-602. https://doi.org/10.11817/j.issn.1672-7347.2020.200211
Gong S, et al. Antiviral Therapy for Coronavirus Disease 2019. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28;45(5):598-602. PubMed PMID: 32879113.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiviral therapy for coronavirus disease 2019. AU - Gong,Subo, AU - Su,Jing, AU - Yan,Xianghong, AU - Li,Fang, AU - Hu,Lang, AU - Liu,Shaokun, PY - 2020/9/4/entrez PY - 2020/9/4/pubmed PY - 2020/9/9/medline KW - antiviral drugs KW - coronavirus disease 2019 KW - severe acute respiratory syndrome coronavirus 2 SP - 598 EP - 602 JF - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences JO - Zhong Nan Da Xue Xue Bao Yi Xue Ban VL - 45 IS - 5 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the outbreak of coronavirus disease 2019 in Wuhan City, China. The SARS-CoV-2 is genetically similar to the coronavirus derived from bat. The SARS-CoV-2, the SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV) all belong to beta coronavirus. Since the outbreak of the coronavirus disease 2019, effective antiviral drugs have become a hot issue in the world. Very little about SARS-CoV-2 is known and there is no precedent for treatment. The National Health Commission has repeatedly revised the diagnosis and treatment guide for the coronavirus disease 2019. The latest guide is "New Coronary Virus-Infected Pneumonia Diagnosis and Treatment Plan (Seventh Trial Version)"(short for Seventh Version of Diagnosis and Treatment Plan). But the use of antiviral drugs is still on trial and no rigorous clinical trials data is available. Hot anti-SARS-CoV-2 drugs include interferon α, ribavirin, lopinavir/ritonavir, chloroquine phosphate, abidol, as well as hydroxychloroquine sulfate and remdesivir. But the later 2 drugs aren't mentioned in the Seventh Version of Diagnosis and Treatment Plan. SN - 1672-7347 UR - https://www.unboundmedicine.com/medline/citation/32879113/Antiviral_therapy_for_coronavirus_disease_2019_ L2 - http://xbyxb.csu.edu.cn/xbwk/fileup/PDF/202005598.pdf DB - PRIME DP - Unbound Medicine ER -